Drugs for neglected diseases: a failure of the market and a public health failure?
Version of Record online: 13 JAN 2002
Tropical Medicine & International Health
Volume 6, Issue 11, pages 945–951, November 2001
How to Cite
Trouiller, P. , Torreele, E. , Olliaro, P. , White, N. , Foster, S. , Wirth, D. and Pécoul, B. (2001), Drugs for neglected diseases: a failure of the market and a public health failure?. Tropical Medicine & International Health, 6: 945–951. doi: 10.1046/j.1365-3156.2001.00803.x
- Issue online: 13 JAN 2002
- Version of Record online: 13 JAN 2002
- 11999) Respective contributions of the public and private sector in the development of new drugs: implications for drug access in the developing world. Working paper on the international conference ‘Drugs for communicable diseases: stimulating development and securing availability’ October 14–15, 1999, Paris.(
- 32000) Will patents on human genes encourage research or stifle it? New Scientist 166 , 15–15.& (
- 7Fortune 500 (2001) Top Performing Industries.http://www.fortune500.com.
- 82001) Global Competitiveness in Pharmaceuticals, a European Perspective. Report prepared for the Directorate General Enterprise of the European Commission. http://europa.eu.int/comm/enterprise/library/enterprise-papers/pdf/enterprise_paper_012001.pdf., , (
- 9Global Forum for Health Research (1999) The 10/90 Report on Health Research 1999, Geneva. http://www.globalforumhealth.org
- 13IMS (1999) IMS Health Global Insight Reports. http://www.ims-global.com.
- 141999) Updating the Cost of a New Chemical Entity. Office of Health Economics, London.(
- 151997) Call for more reliable costs data on clinical trials. Marketletter 13 , 24–25.(
- 161998) The normalisation of the international market for pharmaceuticals: future impacts in emerging markets. In: Medicines and the New Economic Environment (eds F Lobo & G Velasquez). Biblioteca Civitas Economia y Empresa, 1998; Madrid, Espańa, pp. 77–97.(
- 181998) Programmes Promoting Drug Development: WHO Experiences. WHO/DAP/98.6. World Health Organization, Geneva.& (
- 201999) Helping the world’s poorest. Economist August 14 , 17–20.(
- 221999) Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts. Tropical Medicine and International Health 4 , 412–420.DOI: 10.1046/j.1365-3156.1999.00420.x, , , (
- 232001) Legal and regulatory issues affecting drug development for neglected diseases. Working paper of the Drugs for Neglected Diseases Working Group, http://www.neglecteddiseases.org/03.pdf., , (
- 251999) Globalization and Access to Drugs. Perspectives on the WTO/Trips Agreement. WHO/DAP/98.9. World Health Organization, Geneva.& (
- 261997) Globalization and harmonization of regulatory issues: the WHO perspective of developing countries’ needs and perspectives. Drug Information Journal 31 , 895–898.(
- 28World Health Organization (1999) The World Health Report 1999. WHO, Geneva.